Paul Goldberg
Paul Goldberg

Editor & Publisher

Paul Goldberg is the editor and publisher of The Cancer Letter. He joined the publication in 1986.

His coverage has had a profound impact on the field of oncology, leading to numerous Congressional investigations, and helped change policy, regulation, and standards of care.

Paul’s reporting has been recognized by the Washington DC Professional Chapter of the Society of Professional Journalists, the Gerald Loeb Awards, the Association of Health Care Journalists, and the Newsletter and Electronic Publishers Foundation.

His articles have appeared in The New York Times, The Wall Street Journal, The Washington Post and The Washington Monthly, and he has been featured on 60 Minutes, 20/20, CNN and NPR. He is also a novelist and author of nonfiction books.

His author website is

Paul graduated from Duke University with a B.A. in economics in 1981.


Latest Stories

Conversation with The Cancer Letter
FDA officials said the questions about accelerated approval of PD-1 and PD-L1 drugs have been largely resolved, thanks in part to guidance from the Oncologic Drugs Advisory Committee.
Joseph R. Bertino, a physician who made fundamental discoveries in cancer biology, defined curative cancer treatment regimens, trained generations of influential cancer researchers, ran productive laboratories, and served as the inaugural director of Yale Cancer Center, died on Oct. 10. He was 91.
An argument can be made that only a government research agency like NCI has the capacity to answer questions about monitoring pancreatic cysts—and how some of them turn malignant.
Prevention and early detection trials have been especially vulnerable to being disrupted by the COVID-19 lockdown, and a comparison of two regimens for monitoring pancreatic cysts—EA2185—was more vulnerable than most.
Prevention and early detection studies frequently require engaging physicians from specialties other than oncologists, said Peter O’Dwyer and Mitchell Schnall, co-chairs of ECOG-ACRIN Cancer Research Group.
Conversation with The Cancer Letter
Randall F. Holcombe has a goal: earn the NCI designation for University of Vermont Cancer Center. Or, to be precise, earn back the NCI designation.